Similar articles

• Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.

  Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL; SYMPLICITY HTN-3 Investigators. Bakris GL, et al. J Am Coll Cardiol. 2014 Sep 16;64(11):1071-8. doi: 10.1016/j.jacc.2014.05.012. Epub 2014 May 20. J Am Coll Cardiol. 2014. PMID: 24858423 Clinical Trial.
• Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan.

  Kario K, Bhatt DL, Brar S, Cohen SA, Fahy M, Bakris GL. Kario K, et al. Hypertension. 2015 Dec;66(6):1130-7. doi: 10.1161/HYPERTENSIONAHA.115.06260. Epub 2015 Oct 5. Hypertension. 2015. PMID: 26558819
• Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation: The DENERHTN Study (Renal Denervation for Hypertension).

  Gosse P, Cremer A, Pereira H, Bobrie G, Chatellier G, Chamontin B, Courand PY, Delsart P, Denolle T, Dourmap C, Ferrari E, Girerd X, Michel Halimi J, Herpin D, Lantelme P, Monge M, Mounier-Vehier C, Mourad JJ, Ormezzano O, Ribstein J, Rossignol P, Sapoval M, Vaïsse B, Zannad F, Azizi M. Gosse P, et al. Hypertension. 2017 Mar;69(3):494-500. doi: 10.1161/HYPERTENSIONAHA.116.08448. Epub 2017 Jan 23. Hypertension. 2017. PMID: 28115517 Clinical Trial.
• Renal denervation for uncontrolled hypertension: critical review of the evidence.

  Chen C, Upadhyay A. Chen C, et al. Curr Opin Nephrol Hypertens. 2017 Mar;26(2):114-122. doi: 10.1097/MNH.0000000000000300. Curr Opin Nephrol Hypertens. 2017. PMID: 27922849 Review.
• Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings.

  Esler M. Esler M. J Am Soc Hypertens. 2014 Aug;8(8):593-8. doi: 10.1016/j.jash.2014.06.001. Epub 2014 Jun 12. J Am Soc Hypertens. 2014. PMID: 25151320 Review.